RxDoctor Payments Data

Angelo Mallozzi, MD

Family Medicine · Stamford, CTNPI 1689768558

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 71 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$226
  • Esperion Therapeutics, Inc.$222
  • AstraZeneca$168
  • Novo Nordisk$163
  • AbbVie$113
  • Novartis$99
  • plus $620 from 12 others

What the payments were for

  • Food & beverage$1,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,610 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$129,591
Medicare patients
455
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$152,715
OzempicSemaglutide86$114,682
JanuviaSitagliptin Phosphate117$110,828
IngrezzaValbenazine Tosylate20$84,782
JardianceEmpagliflozin50$59,051
XareltoRivaroxaban56$47,377
TradjentaLinagliptin54$45,947
MyrbetriqMirabegron60$31,561
FarxigaDapagliflozin Propanediol38$27,465
LinzessLinaclotide28$23,379
MounjaroTirzepatide22$22,899
Breo ElliptaFluticasone/Vilanterol43$19,366
JentaduetoLinagliptin/Metformin Hcl12$17,676
RexultiBrexpiprazole11$16,189
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$226$152,715218 claims
Novo NordiskOzempic$163$114,68286 claims
GSKBreo Ellipta, Trelegy Ellipta$31$34,87361 claims
AstraZenecaFarxiga, Symbicort$168$34,85257 claims
Astellas Pharma US IncMyrbetriq$22$31,56160 claims
AbbVieLinzess$113$23,37928 claims
Lilly USA, LLCMounjaro$55$22,89922 claims
Otsuka America Pharmaceutical, Inc.Rexulti$90$16,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →